



Pharmacogenomics: Current Status and Future Perspectives

Guest Editor:

Dr. Marta Miarons Font
Hospital Universitari Vall
d'Hebron, Barcelona, Spain

Deadline for manuscript
submissions:
closed (5 February 2024)

Message from the Guest Editor

The purpose of this Special Issue, “Pharmacogenomics: Current Status and Future Perspectives”, is two-fold: (1) to shed light on the progress made in the last years in the Pharmacogenetics and Pharmacogenomics field and on its future challenges to provide a thorough overview of the state of the art in this area of research, and (2) to focus on new insights, novel developments, current challenges, latest discoveries, recent advances and future perspectives in this field.

This Special Issue aims to collect articles to increase the knowledge in the pharmacogenetics area and its implementation in the clinical setting. In this Special Issue, original research articles and reviews are welcome. Research areas may include the following: pharmacogenetics, clinical implementation of pharmacogenetics and identification of genetic factors associated with drug responses in clinical setting, between others.

I would like to invite you, experts and beginners in the field of pharmacogenomics, to contribute to this Special Issue with your research, in order to accelerate the implementation of pharmacogenomic procedures in drug development and clinical practice.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)